Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease ; volume:10 ; number:1 ; day:15 ; month:1 ; year:2018 ; pages:1-9 ; date:12.2018
Alzheimer's research & therapy ; 10, Heft 1 (15.1.2018), 1-9, 12.2018
- Keyword
-
Hirnkrankheit
Neuropsychiatrie
Nervenkrankheit
- Creator
-
Duits, Flora H.
- Contributor
-
Brinkmalm, Gunnar
Teunissen, Charlotte E.
Brinkmalm, Ann
Scheltens, Philip
Van der Flier, Wiesje M.
Zetterberg, Henrik
Blennow, Kaj
SpringerLink (Online service)
- DOI
-
10.1186/s13195-017-0335-x
- URN
-
urn:nbn:de:1111-20180415549
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Duits, Flora H.
- Brinkmalm, Gunnar
- Teunissen, Charlotte E.
- Brinkmalm, Ann
- Scheltens, Philip
- Van der Flier, Wiesje M.
- Zetterberg, Henrik
- Blennow, Kaj
- SpringerLink (Online service)
Other Objects (12)
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer’s disease
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer’s disease
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer’s disease
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future